Stefan Herr

Founding Partner & Managing Director at EMBL Ventures GmbH

Stefan Herr

Stefan Herr

Founding Partner & Managing Director at EMBL Ventures GmbH

Biography

Affectis:
Dr. Stefan Herr is Managing Director at EMBL Ventures based in Heidelberg Germany. He led several investments in Europe and the US for EMBL Ventures, Heidelberg Innovation and a Business Angel. Before joining EMBL Ventures, he served as Managing Director of Verivox, a 3i backed start-up company. Previously, Dr. Herr was Vice President at Heidelberg Innovation and Director Cooperations and Licensing at Hagenuk. Dr. Herr earned his PhD in Physics from the University of Heidelberg and received additional training in law and business at the University of Hagen. He was a recipient of the Boehringer Ingelheim fellowship and is an alumni of the European Molecular Biology Laboratory Ph.D. program.

Overview
RelSci Relationships

52

Number of Boards

2

Relationships
RelSci Relationships are individuals Stefan Herr likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Acousia Therapeutics GmbH

Relationship likelihood: Strong

Founding Partner at EMBL Ventures GmbH

Relationship likelihood: Strong

Venture Partner at EMBL Ventures GmbH

Relationship likelihood: Strong

Venture Partner at EMBL Ventures GmbH

Relationship likelihood: Strong

Head-Chemical Biology at The European Molecular Biology Laboratory

Relationship likelihood: Strong

Head of Resource Development at The European Molecular Biology Laboratory

Relationship likelihood: Strong

Financial Manager at EMBL Ventures GmbH

Relationship likelihood: Strong

General Partner at LSP Management Group BV

Relationship likelihood: Average

Managing Director at Stichting Administratiekantoor Endavit

Relationship likelihood: Average

President & Chief Executive Officer at Lycera Corp.

Relationship likelihood: Average

Paths to Stefan Herr
Potential Connections via
Relationship Science
You
Stefan Herr
Founding Partner & Managing Director at EMBL Ventures GmbH
Education

Heidelberg University sees itself as a research university with a strong international orientation. Besides enhancing its disciplinary strengths, the University places special emphasis on maintaining the dialogue across traditional subject boundaries. Heidelberg University has twelve faculties with a total of more than 30,000 students and a research and teaching staff of more than 5,000 scientists - among them 450 professors. Numerous great minds have learned, taught and conducted research at Heidelberg University. The oldest German university has thus played an important part in shaping science and society since its founding in 1386. The University is at the centre of a research network that includes a large number of non-university research institutions and companies in Heidelberg and the Rhine-Neckar region.

Career History
Founding Partner & Managing Director
2001 - Current

EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties.The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position.EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept.

Boards & Committees
Member, Supervisory Board
Prior

Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany.

Member-Supervisory Board
Prior

Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany.

Transactions
Details Hidden

Bruker Corp. purchases Luxendo GmbH from EMBL Ventures GmbH, LSP Management Group BV

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Stefan Herr. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Stefan Herr's profile does not indicate a business or promotional relationship of any kind between RelSci and Stefan Herr.